Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpectRx Cervical Cancer Test Trial Begins In June; Panel Review Anticipated

This article was originally published in The Gray Sheet

Executive Summary

SpectRx expects that data from a pivotal study of its non-invasive cervical cancer detection system will undergo FDA Obstetrics & Gynecology Devices Panel scrutiny after a PMA is submitted
Advertisement

Related Content

MediSpectra Luma Cervical Imaging System Granted Expedited Review
MediSpectra Luma Cervical Imaging System Granted Expedited Review
SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
Advertisement
UsernamePublicRestriction

Register

MT020251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel